8-K: Wellgistics Health to Acquire Peek Healthcare Technologies, Expanding Digital Prescription Platform

Wellgistics Health, Inc. announces a definitive agreement to acquire Peek Healthcare Technologies, Inc., a digital prescription shopping platform, to enhance its healthcare technology and pharmaceutical services.

Summary

• Wellgistics Health, Inc. (WGRX) has agreed to acquire Peek Healthcare Technologies, Inc., which operates a digital prescription shopping platform called Peek Meds Marketplace.
• The acquisition aims to expand Wellgistics Health's digital healthcare ecosystem and provide consumers with real-time pricing transparency for medications.
• Peek's platform is expected to be immediately accretive to earnings and expand Wellgistics Health's total addressable market.
• Peek also operates a consulting division for brand-name and specialty-lite drug manufacturers, which will be complemented by Wellgistics Health's capabilities.
• Following the acquisition, Peek will operate as a wholly-owned subsidiary of Wellgistics Health, maintaining its brand identity.
• The transaction includes a cash payment of $2,000,000, minus certain adjustments, and an unsecured promissory note of $6,000,000 with 4.5% interest, maturing in three years.
• Peek stockholders will receive 1,777,778 shares of Wellgistics Health common stock, with 507,615 shares guaranteed and 1,270,163 shares subject to forfeiture based on achieving $8,800,000 in revenue by December 31, 2027.
• Wellgistics Health has also entered into an equity purchase agreement with Hudson Global Ventures, LLC, for up to $50,000,000 in shares of common stock over a 24-month period.
• The purchase price for these shares will be 90% of the closing price on the day preceding the purchase notice or 90% of the average closing price during the three trading days after the purchase notice, whichever is lower.
• Wellgistics Health issued 152,000 shares of common stock to Hudson Global Ventures as a commitment fee and paid $15,000 for legal expenses.
• Sajid Sayed resigned as a director of Wellgistics Health, and Michael L. Peterson was appointed to fill the vacancy and will serve as Chairman of the Audit Committee.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the acquisition of Peek and potential access to additional capital. However, there are risks associated with achieving revenue targets and potential dilution from the equity purchase agreement.

Positives

• The acquisition of Peek is expected to be immediately accretive to earnings.
• The acquisition expands Wellgistics Health's total addressable market.
• The Peek platform aligns with Wellgistics Health's mission to create a more affordable and accessible prescription experience.
• The equity purchase agreement with Hudson Global Ventures provides potential access to additional capital of up to $50,000,000.
• The addition of Michael L. Peterson to the board brings an independent director who qualifies under Nasdaq rules.

Negatives

• 1,270,163 shares of Wellgistics Health common stock are subject to forfeiture if Peek does not meet revenue targets.
• The equity purchase agreement with Hudson Global Ventures could dilute existing shareholders if the company directs the investor to purchase shares.
• The company issued 152,000 shares of common stock to Hudson Global Ventures as a commitment fee which dilutes existing shareholders.

Risks

• Failure to achieve the revenue target of $8,800,000 by December 31, 2027, will result in the forfeiture of 1,270,163 shares of Wellgistics Health common stock.
• The equity purchase agreement with Hudson Global Ventures is subject to market conditions and the trading price of Wellgistics Health's common stock.
• The company must obtain stockholder approval to issue an aggregate number of shares of common stock to the Investor, under the ELOC Purchase Agreement, in excess of 19.99% of the number of shares of Common Stock outstanding immediately prior to the execution of the ELOC Purchase Agreement.
• The company may not direct the Investor to purchase ELOC Shares within thirty (30) days of the date of the ELOC Purchase Agreement, if (i) the Company first provides a written first right of refusal to the Investor with respect to such Variable Rate Transaction along with a description of the terms of such transaction and (ii) the Investor does not agree to enter into such Variable Rate Transaction within five (5) trading days thereafter.

Future Outlook

Wellgistics Health intends to expand its digital healthcare ecosystem and create a more affordable, accessible, and patient-centric prescription experience. The company expects Peek to be immediately accretive to earnings and significantly expand its total addressable market.

Management Comments

• Brian Norton, Chief Executive Officer of Wellgistics Health, stated that access to clear and transparent medication pricing should be a right, not a privilege.
• Brian Norton believes the Peek platform aligns with their mission to reimagine healthcare delivery.
• Michael Navin, Chief Executive Officer and Founder of Peek, stated that partnering with Wellgistics Health allows them to scale their consumer offerings and strengthen their value proposition to pharmaceutical manufacturers.

Industry Context

The acquisition occurs within the context of increasing U.S. retail prescription drug spending and regulatory momentum for price transparency, such as the Consolidated Appropriations Act of 2021 (CAA). Consumer-driven prescription shopping is expected to grow rapidly.

Comparison to Industry Standards

• CVS Health acquired Aetna in 2018 for $69 billion, integrating a major health insurer with a pharmacy benefit manager and retail pharmacy chain.
• UnitedHealth Group acquired OptumRx, a pharmacy benefit manager, to integrate pharmacy services with its insurance offerings.
• Amazon acquired PillPack for $753 million in 2018, entering the online pharmacy market and disrupting traditional pharmacy models.
• Teladoc Health acquired Livongo for $18.5 billion in 2020, combining telehealth services with chronic disease management.
• The Wellgistics Health acquisition of Peek Healthcare Technologies is a smaller transaction but follows the trend of integrating technology and pharmaceutical services to improve patient access and transparency.

Management Changes

Corporate Governance

Related Party Transactions

• The company issued a promissory note to Sansur Associates, LLC, which is beneficially owned by Suren Ajjarapu, the Chairman of the Company's board of directors.

Stakeholder Impact

• Shareholders: Potential for increased earnings and market expansion, but also risk of dilution.
• Employees: Integration of Peek's employees into Wellgistics Health.
• Customers: Access to a more comprehensive and transparent prescription experience.
• Pharmaceutical Manufacturers: Access to a fully integrated suite of commercialization services.

Next Steps

• Obtain necessary approvals from Wellgistics Health's stockholders for the issuance of shares under the Merger Agreement.
• Complete the acquisition of Peek Healthcare Technologies, Inc.
• Integrate Peek's platform and consulting division into Wellgistics Health's existing operations.
• File a registration statement for the resale of shares issued under the equity purchase agreement with Hudson Global Ventures, LLC.

Key Dates

Keywords

acquisition, healthcare technology, pharmaceutical services, digital prescription platform, merger, equity purchase agreement, revenue, Wellgistics Health, Peek Healthcare Technologies, financing